BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

ClinicalTrials.gov ID: NCT01930890

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01930890. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB023 in participants with lupus nephritis (LN).

Study identification

NCT ID: NCT01930890
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Biogen; Industry
Enrollment: 87 participants

Conditions and interventions

Conditions

Lupus Nephritis

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 19 Years to 76 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2013 (Type not available)
Primary completion: Jan 2016 (Actual)
Completion: Jan 2016 (Actual)
Last update posted: Jan 18, 2017

2013 – 2016

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
Research Site	Lake Success	New York	11020	—
Research Site	Columbus	Ohio	43210	—
Research Site	Memphis	Tennessee	38119	—
Research Site	El Paso	Texas	79905	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01930890, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 18, 2017 · Synced Nov 13, 2026